Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immix Biopharma, Inc. (IMMX : NSDQ)

• Company Description    Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $2.10 Daily Weekly Monthly 20 Day Moving Average: 173,362 shares Shares Outstanding: 28.83 (millions) Market Capitalization: $60.55 (millions) Beta: 0.25 52 Week High: $3.20 52 Week Low: $1.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.11% -5.80% 12 Week -12.13% -20.19% Year To Date -4.55% -9.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11400 WEST OLYMPIC BLVD SUITE 200 - LOS ANGELES,CA 90064 USA ph: 310-651-8041 fax: - None http://www.immixbio.com

• General Corporate Information    Officers Ilya Rachman - Chief Executive Officer and Chairman Gabriel Morris - Chief Financial Officer and Director Jason Hsu - Director Magda Marquet - Director Helen C. Adams - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45258H106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 28.83 Most Recent Split Date: (:1) Beta: 0.25 Market Capitalization: $60.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.62 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.58 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -46.67% vs. Previous Quarter: -46.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -205.35 03/31/25 - -130.02 12/31/24 - -105.01 ROA 06/30/25 - -110.63 03/31/25 - -86.33 12/31/24 - -77.69 Current Ratio 06/30/25 - 1.23 03/31/25 - 1.80 12/31/24 - 2.33 Quick Ratio 06/30/25 - 1.23 03/31/25 - 1.80 12/31/24 - 2.33 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.17 03/31/25 - 0.34 12/31/24 - 0.48 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©